Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
INTELLIPHARMACEUT
(NQ:
IPCI
)
2.560
USD
-0.010 (-0.39%)
Official Closing Price
/ Updated:
8:10 PM EST, Mar 3, 2015
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
42,332
Open
2.550
Bid (Size)
2.560 (300)
Ask (Size)
2.590 (100)
Prev. Close
2.570
Today's Range
2.550 - 2.560
52wk Range
1.941 - 5.180
Shares Outstanding
23,456,611
Dividend Yield
N/A
Performance
YTD
+9.87%
+9.87%
1 Month
+15.84%
+15.84%
3 Month
-11.72%
-11.72%
6 Month
+1.99%
+1.99%
1 Year
-35.03%
-35.03%
Top News
More News
Intellipharmaceutics Announces 2014 Year End Results With a 48% Reduction in Operating Loss
February 23, 2015
from
GlobeNewswire News Releases
Intellipharmaceutics Reports the Signing of an Exclusive Licensing and Manufacturing Agreement With Teva Pharmaceuticals USA, Inc. for an Extended Release Oral Drug Product Candidate
February 02, 2015
from
GlobeNewswire News Releases
More News
Read More
Intellipharmaceutics Notes Launch of 5mg Strength of Focalin XR(R) Generic by Teva
November 20, 2014
from
GlobeNewswire News Releases
Intellipharmaceutics Announces Appointment of New Chief Financial Officer
November 18, 2014
from
GlobeNewswire News Releases
Intellipharmaceutics Reports That the FDA Has Given Its Toronto Manufacturing Facility an "Acceptable" Classification
October 27, 2014
from
GlobeNewswire News Releases
Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of Regabatin(TM) XR (Pregabalin Extended-Release)
October 22, 2014
from
GlobeNewswire News Releases
Intellipharmaceutics Announces Third Quarter 2014 Results
October 15, 2014
from
GlobeNewswire News Releases
Profound Medical Appoints Shameze Rampertab as Chief Financial Officer
October 15, 2014
from
GlobeNewswire News Releases
Intellipharmaceutics Announces Resignation of Chief Financial Officer
September 30, 2014
from
GlobeNewswire News Releases
Intellipharmaceutics Is 'Not Just A Generic Drug Story,' Brean Capital Says
February 23, 2015
category
Analyst Ratings
,
Benzinga
,
Brean Capital
, and 2 more.
from
Benzinga
I.CA Makes Bullish Cross Above Critical Moving Average
February 23, 2015
category
Dividends
from
Dividend Channel
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates
Bots go here